Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00995410 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers
A Phase 3 study, sponsored by POZEN.
- Completed
- Registry status
- Phase 3
- Development phase
- 380
- Enrollment target
NCT00995410 is a Phase 3 study that has completed, run by POZEN. The registered enrollment target is 380 participants.
The verdict
NCT00995410, a Phase 3 study, has completed, sponsored by POZEN.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 380 participants
- Enrollment target
Study Summary
This study uses an open-label design and will be conducted in approximately 40 sites in the United States. Approximately 400 subjects will be enrolled in the study to ensure that approximately 300 subjects will have 6 months exposure to PA32540 and at least 100 subjects will have 12 months exposure to PA32540.
Interventions
- DRUG PA32540
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 380 participants |
| Start Date | 2009-10 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00995410
The ClinicalTrials.gov registry entry for NCT00995410 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 380 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is POZEN, which has 24 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PA32540 is the first listed.
NCT00995410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00995410 about?
NCT00995410 is a clinical study titled "Study to Evaluate the Long-Term Safety of PA32540 in Subjects Who Are at Risk for Developing Aspirin-Associated Gastric Ulcers". This study uses an open-label design and will be conducted in approximately 40 sites in the United States. Approximately 400 subjects will be enrolled in the study to ensure that approximately 300 subjects will have 6 months exposure to PA32540 and at least 100 subjects will have 12 months exposure ...
What is the current status of trial NCT00995410?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 380 participants. The study started on 2009-10. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00995410?
The interventions under investigation include: PA32540 (DRUG).
Who is sponsoring clinical trial NCT00995410?
This trial is sponsored by POZEN, which has 24 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.